Xenon Pharmaceuticals Inc. (XENE)
Xenon Pharmaceuticals Inc. (XENE) from its SEC filings: 2025 revenue $7.5 million, net margin -4612%, free cash flow -$279.9 million. Insider trades, recent filings and a price chart. Free.
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Revenue (2025) | $7.5 million |
| Net income | -$345.9 million |
| Net margin | -4612.1% |
| Free cash flow | -$279.9 million |
| Diluted EPS | $-4.36 |
| Cash | $119.5 million |
| Long-term debt | $10.9 million |
| Share count, 1 year | +26% |
| Fundamentals check | Weak fundamentals |
Source: SEC EDGAR company filings (XBRL), updated 2026-10-24. Education only, not financial advice.